{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:01:30Z","timestamp":1773392490897,"version":"3.50.1"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Azithromycin, administered with ceftriaxone, is recommended by the CDC for the treatment of gonorrhea. Many experts have expressed concern about the ease with which\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Neisseria gonorrhoeae<\/jats:named-content>\n            can acquire macrolide resistance. We sought to describe gonococcal azithromycin susceptibility in the United States and to determine whether azithromycin susceptibility has changed over time. We analyzed data from 2005 to 2013 from the Gonococcal Isolate Surveillance Project, a CDC-supported sentinel surveillance network that monitors gonococcal antimicrobial susceptibility. A total of 44,144\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            isolates were tested for azithromycin susceptibility by agar dilution methods. The overall azithromycin MIC\n            <jats:sub>50<\/jats:sub>\n            was 0.25 \u03bcg\/ml, and the MIC\n            <jats:sub>90<\/jats:sub>\n            was 0.5 \u03bcg\/ml. There were no overall temporal trends in geometric means. Isolates from men who had sex with men had significantly higher geometric mean MICs than isolates from men who had sex exclusively with women. The overall prevalence of reduced azithromycin susceptibility (MIC, \u22652 \u03bcg\/ml) was 0.4% and varied by year from 0.3% (2006 and 2009) to 0.6% (2013). We did not find a clear temporal trend in gonococcal azithromycin MICs in the United States, and the prevalence of reduced azithromycin susceptibility remains low. These findings support the continued use of azithromycin in a combination therapy regimen for gonorrhea.\n          <\/jats:p>","DOI":"10.1128\/aac.04337-14","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T04:56:55Z","timestamp":1417496215000},"page":"998-1003","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Analysis of Neisseria gonorrhoeae Azithromycin Susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013"],"prefix":"10.1128","volume":"59","author":[{"given":"Robert D.","family":"Kirkcaldy","sequence":"first","affiliation":[{"name":"Division of STD Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olusegun","family":"Soge","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Papp","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Edward W.","family":"Hook","sequence":"additional","affiliation":[{"name":"University of Alabama and Jefferson County Department of Health, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Kubin","sequence":"additional","affiliation":[{"name":"Texas Department of State Health Services, Austin, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard S.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"2012 STD Surveillance Report","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. 2014. 2012 STD Surveillance Report. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-195807000-00018"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3109\/00016346509158538","article-title":"Treatment of acute non-tuberculous salpingitis with antibiotics alone and in combination with glucocorticoids: a prospective double blind controlled study of the clinical course and prognosis","volume":"44","author":"Falk V","year":"1965","unstructured":"Falk V. 1965. Treatment of acute non-tuberculous salpingitis with antibiotics alone and in combination with glucocorticoids: a prospective double blind controlled study of the clinical course and prognosis. Acta Obstet Gynecol Scand 44(Suppl 6):S3\u2013S118.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"e_1_3_3_5_2","first-page":"1041","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae\u2014Hawaii and California, 2001","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae\u2014Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 51:1041\u20131044.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/144.2.191"},{"key":"e_1_3_3_7_2","first-page":"332","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56:332\u2013336.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_8_2","first-page":"335","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men\u2014United States, 2003, and revised recommendations for gonorrhea treatment, 2004","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","unstructured":"Centers for Disease Control and Prevention. 2004. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men\u2014United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 53:335\u2013338.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_9_2","first-page":"873","article-title":"Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000\u20132010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000\u20132010. MMWR Morb Mortal Wkly Rep 60:873\u2013877.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_10_2","first-page":"590","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590\u2013594.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit084"},{"issue":"12","key":"e_1_3_3_12_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend Rep 59(RR-12):1\u2013110.","journal-title":"MMWR Recommend Rep"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.OLQ.0000109514.91508.FC"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2468"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00039-6"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3182685d2b"},{"key":"e_1_3_3_17_2","first-page":"579","article-title":"Neisseria gonorrhoeae with reduced susceptibility to azithromycin\u2014San Diego County, California, 2009","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Neisseria gonorrhoeae with reduced susceptibility to azithromycin\u2014San Diego County, California, 2009. MMWR Morb Mortal Wkly Rep 60:579\u2013581.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450110059027"},{"key":"e_1_3_3_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 21st informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_20_2","volume-title":"Gonococcal Isolate Surveillance Project (GISP): protocol","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. 2014. Gonococcal Isolate Surveillance Project (GISP): protocol. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/std\/gisp\/GISP-Protocol-May-2014.pdf."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1212055"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1163"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0904.020268"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462971920127"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.14.19833-en"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3020-3025.2002"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00309-10"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2009.0008"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0188"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029407"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/522964"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181b61bb1"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn235"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir929"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02093-13"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02608-13"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050905"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050906"},{"key":"e_1_3_3_39_2","volume-title":"GRASP: The Gonococcal Resistance to Antimicrobials Surveillance Programme: annual report","author":"Health Protection Agency","year":"2008","unstructured":"Health Protection Agency. 2008. GRASP: The Gonococcal Resistance to Antimicrobials Surveillance Programme: annual report. Health Protection Agency, London, United Kingdom. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1221117895841."},{"key":"e_1_3_3_40_2","volume-title":"GRASP 2012 report: The Gonococcal Resistance to Antimicrobials Surveillance Programme","author":"Public Health England","year":"2012","unstructured":"Public Health England. 2012. GRASP 2012 report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. Public Health England, London, United Kingdom. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317140152190."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00004"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1099\/13500872-141-4-907"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04337-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04337-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:54:47Z","timestamp":1645484087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04337-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1128\/AAC.04337-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04337-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"2014-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}